This page shows the latest Ligelizumab news and features for those working in and with pharma, biotech and healthcare.
Novartis picked up ligelizumab following its acquisition of UK firm Ziarco in 2016. ... If all goes to plan, Novartis is set to file ligelizumab by the end of 2021.
Ligelizumab (QGE031), a new treatment for chronic spontaneous urticaria, which has phase 3 results and is due to be filed with regulators by the end of 2021.
fevipiprant (QAW039) in phase II and ligelizumab (QGE031) for CIU.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...